{"id":23646,"date":"2025-08-22T17:06:52","date_gmt":"2025-08-22T11:36:52","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=23646"},"modified":"2025-09-10T10:49:50","modified_gmt":"2025-09-10T05:19:50","slug":"multiple-system-atrophy-treatment","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/multiple-system-atrophy-treatment","title":{"rendered":"Evolving Landscape of Multiple System Atrophy Treatment: Recent Developments and Future Directions"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-69d375cd6bece\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-69d375cd6bece\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/multiple-system-atrophy-treatment\/#Neurodegenerative_Connections_Similarities_Between_Multiple_System_Atrophy_and_Parkinsons_Disease\" >Neurodegenerative Connections: Similarities Between Multiple System Atrophy and Parkinson\u2019s Disease<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/multiple-system-atrophy-treatment\/#Promising_Therapies_and_Future_Scenarios_for_Multiple_System_Atrophy_Treatment\" >Promising Therapies and Future Scenarios for Multiple System Atrophy Treatment<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/multiple-system-atrophy-treatment\/#FAQs\" >FAQs<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/multiple-system-atrophy-treatment\/#FAQs-2\" >FAQs<\/a><\/li><\/ul><\/nav><\/div>\n\n<p><strong>Multiple system atrophy (MSA) <\/strong>is a progressive neurodegenerative disorder characterized by a constellation of symptoms impacting both the autonomic nervous system and motor function. According to the <strong>National Organization for Rare Disorders (NORD)<\/strong>, MSA affects between <strong>15,000 and 50,000<\/strong> individuals in the United States, affecting men and women across all racial groups. The etiology of MSA remains unknown, with the vast majority of cases occurring sporadically and without a clear cause. The peak onset typically occurs between the ages of <strong>55 <\/strong>and <strong>60<\/strong>, although onset can range from as early as 30 to beyond 90 years of age. <strong>NORD <\/strong>estimates the incidence of MSA in the US general population to be approximately <strong>0.6 cases per 100,000<\/strong> persons annually, corresponding to roughly <strong>2,000<\/strong> new diagnoses each year.<\/p>\n\n\n\n<p><em>In the assessment done by DelveInsight, the estimated total <\/em><a href=\"https:\/\/www.delveinsight.com\/report-store\/multiple-system-atrophy-msa-epidemiology-forecast\"><em>diagnosed prevalent cases of multiple system atrophy<\/em><\/a><em> in the 7MM were <\/em><em>~<\/em><strong><em>70K<\/em><\/strong><em> in 2024.<\/em><em> The highest diagnosed prevalent cases of multiple system atrophy were found to be reported in the US compared to the other 7MM countries. As per DelveInsight\u2019s estimates, the country alone accounts for <\/em><strong><em>~60%<\/em><\/strong><em> <\/em><em>of the total diagnosed prevalent cases among the 7MM countries.&nbsp;<\/em>MSA includes two main subtypes: <strong>parkinsonian (MSA-P) <\/strong>and <strong>cerebellar (MSA-C)<\/strong>, with MSA-P accounting for approximately <strong>75%<\/strong> of all MSA cases, making it the more common form. Both subtypes cause significant disability, but MSA-P often resembles Parkinson\u2019s disease, complicating diagnosis. Despite advances, there remains a substantial unmet need for effective treatments and early diagnostic tools for MSA. The rarity and complexity of the disease contribute to delayed diagnosis and limited therapeutic options, highlighting the urgency for enhanced research and targeted therapies to improve patient outcomes.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-neurodegenerative-connections-similarities-between-multiple-system-atrophy-and-parkinson-s-disease\"><span class=\"ez-toc-section\" id=\"Neurodegenerative_Connections_Similarities_Between_Multiple_System_Atrophy_and_Parkinsons_Disease\"><\/span><strong>Neurodegenerative Connections: Similarities Between Multiple System Atrophy and Parkinson\u2019s Disease<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>MSA and Parkinson\u2019s disease are distinct neurodegenerative disorders but share clinical and pathological features, classifying them as synucleinopathies\u2014marked by abnormal alpha-synuclein accumulation. Both present with motor symptoms like bradykinesia, rigidity, and postural instability, impacting daily functioning. However, MSA involves more widespread neurodegeneration, affecting the basal ganglia, cerebellum, and autonomic centers, leading to additional symptoms such as autonomic failure and ataxia. In contrast, Parkinson\u2019s primarily targets dopaminergic neurons in the substantia nigra. While Lewy bodies are common to both, the broader distribution of neuronal damage in MSA accounts for its faster progression and more diverse symptom profile.<\/p>\n\n\n\n<p><strong>Breaking Ground: Promising MSA Treatment Approaches&nbsp;<\/strong><\/p>\n\n\n\n<p>Treatment for both MSA-P and MSA-C is primarily symptomatic. MSA-P may respond partially to Parkinson\u2019s medications though benefits are often limited. MSA-C treatment lacks specific drugs, with care focused on managing balance and coordination issues through physical therapy, occupational therapy, and supportive interventions.<\/p>\n\n\n\n<p>In the approved market segment for <a href=\"https:\/\/www.delveinsight.com\/report-store\/multiple-system-atrophy-msa-market\">multiple system atrophy treatment<\/a>, <strong>droxidopa (NORTHERA)<\/strong> is the world\u2019s first approved medication for symptomatic nOH. <strong>Chelsea <\/strong>received approval for NORTHERA from the US FDA in February 2014 for symptomatic benefit in adult patients with nOH, which is found in the majority of <a href=\"https:\/\/www.delveinsight.com\/report-store\/multiple-system-atrophy-msa-epidemiology-forecast\">multiple system atrophy patients<\/a> and is a leading source of disability and injury in the disease. Since its approval, several generic versions of the drug are now available, increasing accessibility for patients requiring treatment for this condition.&nbsp;<\/p>\n\n\n\n<p>There is currently no approved disease-modifying agent. The drug used to treat Parkinson\u2019s disease, most notably<strong> levodopa (SINEMET),<\/strong> is also administered for multiple system atrophy patients. The efficacy of such drugs, however, varies substantially across affected individuals. Other <a href=\"https:\/\/www.delveinsight.com\/report-store\/parkinsons-disease-market-size-analysis-treatment\">drugs used to treat Parkinson\u2019s disease<\/a>, in addition to levodopa, may be used to treat multiple system atrophy patients. These included dopamine agonists like <strong>ropinirole (REQUIP) and pramipexole (MIRAPEXIN),<\/strong> which boost dopamine receptor activation in the brain. This aids the brain&#8217;s reception of dopamine messages. <strong>Midodrine hydrochloride (PROAMATINE)<\/strong> has been used to treat low blood pressure, which has been linked to multiple system atrophy in certain cases. Low blood pressure can be treated using adrenergic medications such as ephedrine. Low blood pressure can also be treated with L-threo-dihydroxyphenylserine (L-DOPS or Lthreo-DOPS). Midodrine is considered more physiologic and better tolerated than fludrocortisone, while other medicines worth exploring include indomethacin and intranasal desmopressin.&nbsp;<\/p>\n\n\n\n<p>The breadth of treatment options for orthostatic hypotension in multiple system atrophy provides clinicians with some hope of alleviating the misery of many patients. Multiple system atrophy covers the major market with off-label and generic treatments. <strong>Clonazepam, vitamin E, propranolol, baclofen, or amantadine<\/strong> have demonstrated superior efficacy. However, in an open-label experiment with MSA-C patients, buspirone (off-label) improved upper-limb ataxia. Depending on the severity of the other symptoms, drugs such as <strong>sildenafil (VIAGRA), tadalafil (Cialis), or vardenafil (LEVITRA)<\/strong> may be used to treat urinary and erectile dysfunction (ED) symptoms that are common in males with multiple system atrophy.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><a href=\"https:\/\/www.delveinsight.com\/sample-request\/multiple-system-atrophy-msa-market\"><img decoding=\"async\" width=\"1024\" height=\"422\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/06\/25170225\/Multiple-System-Atrophy-Key-Insights-2024-1024x422.webp\" alt=\"Multiple-System-Atrophy-Key-Insights\" class=\"wp-image-33171\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/06\/25170225\/Multiple-System-Atrophy-Key-Insights-2024-1024x422.webp 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/06\/25170225\/Multiple-System-Atrophy-Key-Insights-2024-300x124.webp 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/06\/25170225\/Multiple-System-Atrophy-Key-Insights-2024-150x62.webp 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/06\/25170225\/Multiple-System-Atrophy-Key-Insights-2024-768x316.webp 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/06\/25170225\/Multiple-System-Atrophy-Key-Insights-2024-1536x633.webp 1536w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/06\/25170225\/Multiple-System-Atrophy-Key-Insights-2024.webp 1920w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/a><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Promising_Therapies_and_Future_Scenarios_for_Multiple_System_Atrophy_Treatment\"><\/span><strong>Promising Therapies and Future Scenarios for Multiple System Atrophy Treatment<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Considering all the existing knowledge gaps and the void of effective neuroprotective treatment, some major pharma players are proactive with their early and mid-phase trial candidates in the pursuit of a breakthrough therapy to dominate the multiple system atrophy treatment market. <strong>H Lundbeck A\/S (Lu AF82422), Theravance Biopharma (Ampreloxetine), AstraZeneca\/Takeda Pharma (TAK-341\/MEDI1341), Ono Pharma (ONO-2808), Teva Pharmaceutical\/MODAG GmbH (Emrusolmin), Ionis Pharmaceuticals, Inc.\/Biogen (ION464), Alterity Therapeutics (ATH434)<\/strong><strong>,<\/strong> and others are the leading companies working in the segment with their lead assets in different <a href=\"https:\/\/www.delveinsight.com\/report-store\/multiple-system-atrophy-msa-pipeline-insight\">multiple system atrophy clinical trials<\/a>.<\/p>\n\n\n\n<p>The human Monoclonal Antibody (mAb) <strong>Amlenetug <\/strong>(<strong>Lu AF82422)<\/strong> targets the toxic alpha-synuclein protein, which is a pathogenic characteristic of multiple spinal atrophy. To eliminate these toxic proteins, the chemical operates similarly to the body\u2019s natural immune system. Lu AF82422 may potentially reduce or stop the progression of MSA because it tackles the disease&#8217;s underlying biology, according to Lundbeck. In <strong>February 2025<\/strong>, Lundbeck announced that the US FDA has granted Fast Track designation to amlenetug. Previously, <strong>in April 2024<\/strong>, the US FDA granted Orphan Drug Designation (ODD) to Lundbeck&#8217;s Lu AF82422 for the treatment of MSA. Similarly, the European Medicines Agency (EMA) granted Lu AF82422 ODD status <strong>in April 2021<\/strong>.<\/p>\n\n\n\n<p><strong>Theravance Biopharma\u2019s ampreloxetine<\/strong> is a once-daily Norepinephrine Reuptake Inhibitor (NRI) in development for the treatment of patients with symptomatic neurogenic orthostatic hypotension (nOH). It binds to norepinephrine transporters with a high affinity. Ampreloxetine increases extracellular norepinephrine concentrations by inhibiting the activity of these transporters. Theravance Biopharma recently presented updated Phase 3 data on ampreloxetine at the <strong>International MSA Congress <\/strong>in <strong>May 2025<\/strong>. The REDWOOD 0170 study showed that MSA patients experienced meaningful improvements in neurogenic orthostatic hypotension (nOH) symptoms after 16 weeks of ampreloxetine treatment. Symptoms remained stable in the treatment group but worsened with placebo. Functional activities like standing and walking improved and declined after placebo withdrawal. Despite existing therapies, MSA patients continue to have a high nOH symptom burden, highlighting an unmet need. These results reinforce ampreloxetine\u2019s potential as a promising treatment for nOH in MSA.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><a href=\"https:\/\/www.delveinsight.com\/sample-request\/multiple-system-atrophy-msa-market\"><img decoding=\"async\" width=\"1024\" height=\"290\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/06\/25170525\/Emerging-Therapies-for-Multiple-System-Atrophy-1024x290.webp\" alt=\"Emerging Therapies for Multiple System Atrophy\" class=\"wp-image-33172\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/06\/25170525\/Emerging-Therapies-for-Multiple-System-Atrophy-1024x290.webp 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/06\/25170525\/Emerging-Therapies-for-Multiple-System-Atrophy-300x85.webp 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/06\/25170525\/Emerging-Therapies-for-Multiple-System-Atrophy-150x43.webp 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/06\/25170525\/Emerging-Therapies-for-Multiple-System-Atrophy-768x218.webp 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/06\/25170525\/Emerging-Therapies-for-Multiple-System-Atrophy-1536x435.webp 1536w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/06\/25170525\/Emerging-Therapies-for-Multiple-System-Atrophy.webp 1920w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/a><\/figure>\n\n\n\n<p><strong>Alterity\u2019s<\/strong> lead candidate, <strong>ATH434<\/strong>, is the first of a new generation of small molecules designed to block the aggregation of pathogenic proteins implicated in neurodegeneration. ATH434 decreases the aberrant accumulation of S and tau proteins in animal illness models by restoring normal iron balance in the brain. As a result, it has a high potential for treating various kinds of atypical Parkinsonism. Recently, Alterity Therapeutics announced that the first patient has been enrolled in new Phase II clinical trial investigating ATH434 in individuals with multiple system atrophy (MSA), a type of atypical parkinsonism. The open-label, biomarker ATH434-202 research (NCT05864365) at Vanderbilt University Medical Centre in Tennessee is enrolling 15 persons with advanced MSA and clinical indications of parkinsonism.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>With the expected launch of these emerging therapies, the multiple system atrophy treatment market is expected to show positive growth in the forecast period in the 7MM. As per DelveInsight analysis, the <\/em><a href=\"https:\/\/www.delveinsight.com\/report-store\/multiple-system-atrophy-msa-market\"><em>total multiple system atrophy market size<\/em><\/a><em> in the 7MM was approximately <\/em><strong><em>USD 125 million<\/em><\/strong><em> in 2022 and is projected to increase during the forecast period (2023\u20132032).<\/em><\/p>\n<\/blockquote>\n\n\n\n<p>In recent years, there has been a better understanding of the neuropathological components of multiple system atrophy. In addition, research studies using effective MoAs to treat multiple system atrophy neuroprotective provide significant pharma companies with a plethora of exciting opportunities. As the current diagnostic consensus criteria strive for a step forward, the conclusive diagnosis of multiple system atrophy is opportunistic.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"FAQs\"><\/span><strong>FAQs<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<div class=\"schema-faq wp-block-yoast-faq-block\"><div class=\"schema-faq-section\" id=\"faq-question-1687147349614\"><strong class=\"schema-faq-question\"><strong>1. What is multiple system atrophy?<\/strong><\/strong> <p class=\"schema-faq-answer\">Multiple system atrophy (MSA) is a neurodegenerative disease that causes symptoms that affect both the autonomic nervous system and mobility.<\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1687147362926\"><strong class=\"schema-faq-question\"><strong>2. What are multiple system atrophy symptoms?<\/strong><\/strong> <p class=\"schema-faq-answer\">The slowness of movement, tremors, rigidity, and incoordination are the first indications and multiple system atrophy symptoms. The Parkinsonian type (MSA-P) with primary symptoms similar to Parkinson&#8217;s disease and the cerebellar type (MSA-C) with primary symptoms featuring ataxia are the most significant symptoms of examination.<\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1687147376775\"><strong class=\"schema-faq-question\"><strong>3. How is multiple system atrophy diagnosed?<\/strong><\/strong> <p class=\"schema-faq-answer\">Multiple system atrophy diagnosis is difficult, especially in the early stages, because many of the symptoms are similar to Parkinson\u2019s disease. Autonomic testing, assessment of bladder function, and\/or neuroimaging such as an MRI or PET scan are examples of diagnostic examinations. The diagnosis of multiple system atrophy is also dependent on a thorough medical history and neurological exams; the labels Possible, Probable, and Definite are used to describe different diagnostic phases in MSA cases.<\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1687147390472\"><strong class=\"schema-faq-question\"><strong>4. What are the current multiple system atrophy treatment options?<\/strong><\/strong> <p class=\"schema-faq-answer\">There are currently no treatments available to slow the progression of multiple system atrophy\u2019s neurodegenerations. There are drugs available to help with multiple system atrophy symptoms, such as Levodopa, Amantadine, Droxidopa, Anticholinergic agents, and various off-label therapy.<\/p> <\/div> <\/div>\n\n\n\n<figure class=\"wp-block-image size-large\"><a href=\"https:\/\/www.delveinsight.com\/report-store\/multiple-system-atrophy-msa-market\"><img decoding=\"async\" width=\"1024\" height=\"194\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/01\/27161013\/Multiple-System-Atrophy-Market-Outlook-and-Assessment-1024x194.png\" alt=\"\" class=\"wp-image-30887\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/01\/27161013\/Multiple-System-Atrophy-Market-Outlook-and-Assessment-1024x194.png 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/01\/27161013\/Multiple-System-Atrophy-Market-Outlook-and-Assessment-300x57.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/01\/27161013\/Multiple-System-Atrophy-Market-Outlook-and-Assessment-150x28.png 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/01\/27161013\/Multiple-System-Atrophy-Market-Outlook-and-Assessment-768x145.png 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/01\/27161013\/Multiple-System-Atrophy-Market-Outlook-and-Assessment-1536x291.png 1536w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/01\/27161013\/Multiple-System-Atrophy-Market-Outlook-and-Assessment.png 1584w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/a><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-faqs\"><span class=\"ez-toc-section\" id=\"FAQs-2\"><\/span>FAQs<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<div class=\"schema-faq wp-block-yoast-faq-block\"><div class=\"schema-faq-section\" id=\"faq-question-1757481549608\"><strong class=\"schema-faq-question\"><strong>What is multiple system atrophy prevalence?<\/strong><\/strong> <p class=\"schema-faq-answer\">In the assessment done by DelveInsight, the estimated total diagnosed prevalent cases of multiple system atrophy in the 7MM were ~70K in 2024. The highest diagnosed prevalent cases of multiple system atrophy were found to be reported in the US compared to the other 7MM countries.<\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1757481556145\"><strong class=\"schema-faq-question\"><strong>What are the current multiple system atrophy treatment options?<\/strong><\/strong> <p class=\"schema-faq-answer\">The drug used to treat Parkinson\u2019s disease, most notably levodopa (SINEMET), is used for multiple system atrophy treatment. Other Parkinson\u2019s disease drugs, in addition to levodopa, may be used to treat multiple system atrophy patients. These included dopamine agonists like ropinirole (REQUIP), pramipexole (MIRAPEXIN), and Midodrine hydrochloride (PROAMATINE), among others.<\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1757481566024\"><strong class=\"schema-faq-question\"><strong>Which are the emerging MSA drugs in the clinical trial landscape?<\/strong><\/strong> <p class=\"schema-faq-answer\">H Lundbeck A\/S (Lu AF82422), Theravance Biopharma (Ampreloxetine), AstraZeneca\/Takeda Pharma (TAK-341\/MEDI1341), Ono Pharma (ONO-2808), Teva Pharmaceutical\/MODAG GmbH (Emrusolmin), Ionis Pharmaceuticals, Inc.\/Biogen (ION464), Alterity Therapeutics (ATH434), and others are the leading companies working in the segment with their lead assets in different multiple system atrophy clinical trials.<\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1757481580666\"><strong class=\"schema-faq-question\"><strong>Where is the multiple system atrophy market headed?<\/strong><\/strong> <p class=\"schema-faq-answer\">According to DelveInsight\u2019s analysis, the multiple system atrophy market in the 7MM was valued at approximately USD 43 million in 2023. Over the forecast period from 2024 to 2034, multiple system atrophy market is projected to grow at a CAGR of 44.7%.<\/p> <\/div> <\/div>\n","protected":false},"excerpt":{"rendered":"<p>Multiple system atrophy (MSA) is a progressive neurodegenerative disorder characterized by a constellation of symptoms impacting both the autonomic nervous system and motor function. According to the National Organization for Rare Disorders (NORD), MSA affects between 15,000 and 50,000 individuals in the United States, affecting men and women across all racial groups. The etiology of [&hellip;]<\/p>\n","protected":false},"author":20,"featured_media":23647,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":7,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17],"tags":[20778,20780,20782,20779,20781,1826,2567],"industry":[17225],"therapeutic_areas":[17245],"class_list":["post-23646","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-articles","tag-multiple-system-atrophy","tag-multiple-system-atrophy-market","tag-multiple-system-atrophy-patients","tag-multiple-system-atrophy-treatment","tag-multiple-system-atrophy-treatment-market","tag-parkinsons-disease","tag-samsara-biocapital","industry-pharmaceutical","therapeutic_areas-neurology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Emerging Therapies For Multiple System Atrophy Treatment<\/title>\n<meta name=\"description\" content=\"The multiple system atrophy treatment market is expected to grow significantly owing to the launch of emerging therapies in the coming years.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/multiple-system-atrophy-treatment\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Emerging Therapies For Multiple System Atrophy Treatment\" \/>\n<meta property=\"og:description\" content=\"The multiple system atrophy treatment market is expected to grow significantly owing to the launch of emerging therapies in the coming years.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/multiple-system-atrophy-treatment\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-22T11:36:52+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-09-10T05:19:50+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/06\/19093701\/multiple-system-atrophy-treatment.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"800\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Jatin Vimal\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Jatin Vimal\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"9 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Emerging Therapies For Multiple System Atrophy Treatment","description":"The multiple system atrophy treatment market is expected to grow significantly owing to the launch of emerging therapies in the coming years.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/multiple-system-atrophy-treatment","og_locale":"en_US","og_type":"article","og_title":"Emerging Therapies For Multiple System Atrophy Treatment","og_description":"The multiple system atrophy treatment market is expected to grow significantly owing to the launch of emerging therapies in the coming years.","og_url":"https:\/\/www.delveinsight.com\/blog\/multiple-system-atrophy-treatment","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2025-08-22T11:36:52+00:00","article_modified_time":"2025-09-10T05:19:50+00:00","og_image":[{"width":1200,"height":800,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/06\/19093701\/multiple-system-atrophy-treatment.png","type":"image\/png"}],"author":"Jatin Vimal","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"Jatin Vimal","Est. reading time":"9 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":["WebPage","FAQPage"],"@id":"https:\/\/www.delveinsight.com\/blog\/multiple-system-atrophy-treatment","url":"https:\/\/www.delveinsight.com\/blog\/multiple-system-atrophy-treatment","name":"Emerging Therapies For Multiple System Atrophy Treatment","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/multiple-system-atrophy-treatment#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/multiple-system-atrophy-treatment#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/06\/19093701\/multiple-system-atrophy-treatment.png","datePublished":"2025-08-22T11:36:52+00:00","dateModified":"2025-09-10T05:19:50+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/c846f0323e948c55336d657b654f3158"},"description":"The multiple system atrophy treatment market is expected to grow significantly owing to the launch of emerging therapies in the coming years.","mainEntity":[{"@id":"https:\/\/www.delveinsight.com\/blog\/multiple-system-atrophy-treatment#faq-question-1687147349614"},{"@id":"https:\/\/www.delveinsight.com\/blog\/multiple-system-atrophy-treatment#faq-question-1687147362926"},{"@id":"https:\/\/www.delveinsight.com\/blog\/multiple-system-atrophy-treatment#faq-question-1687147376775"},{"@id":"https:\/\/www.delveinsight.com\/blog\/multiple-system-atrophy-treatment#faq-question-1687147390472"},{"@id":"https:\/\/www.delveinsight.com\/blog\/multiple-system-atrophy-treatment#faq-question-1757481549608"},{"@id":"https:\/\/www.delveinsight.com\/blog\/multiple-system-atrophy-treatment#faq-question-1757481556145"},{"@id":"https:\/\/www.delveinsight.com\/blog\/multiple-system-atrophy-treatment#faq-question-1757481566024"},{"@id":"https:\/\/www.delveinsight.com\/blog\/multiple-system-atrophy-treatment#faq-question-1757481580666"}],"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/multiple-system-atrophy-treatment"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/multiple-system-atrophy-treatment#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/06\/19093701\/multiple-system-atrophy-treatment.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/06\/19093701\/multiple-system-atrophy-treatment.png","width":1200,"height":800,"caption":"multiple-system-atrophy-treatment"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/c846f0323e948c55336d657b654f3158","name":"Jatin Vimal","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/10dcf4b5071c366691525fa20af33b87e8a3897e6d0acc1a2b09a7b99b8d8ae1?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/10dcf4b5071c366691525fa20af33b87e8a3897e6d0acc1a2b09a7b99b8d8ae1?s=96&d=mm&r=g","caption":"Jatin Vimal"},"sameAs":["https:\/\/www.delveinsight.com"]},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/multiple-system-atrophy-treatment#faq-question-1687147349614","position":1,"url":"https:\/\/www.delveinsight.com\/blog\/multiple-system-atrophy-treatment#faq-question-1687147349614","name":"1. What is multiple system atrophy?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"Multiple system atrophy (MSA) is a neurodegenerative disease that causes symptoms that affect both the autonomic nervous system and mobility.","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/multiple-system-atrophy-treatment#faq-question-1687147362926","position":2,"url":"https:\/\/www.delveinsight.com\/blog\/multiple-system-atrophy-treatment#faq-question-1687147362926","name":"2. What are multiple system atrophy symptoms?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"The slowness of movement, tremors, rigidity, and incoordination are the first indications and multiple system atrophy symptoms. The Parkinsonian type (MSA-P) with primary symptoms similar to Parkinson's disease and the cerebellar type (MSA-C) with primary symptoms featuring ataxia are the most significant symptoms of examination.","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/multiple-system-atrophy-treatment#faq-question-1687147376775","position":3,"url":"https:\/\/www.delveinsight.com\/blog\/multiple-system-atrophy-treatment#faq-question-1687147376775","name":"3. How is multiple system atrophy diagnosed?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"Multiple system atrophy diagnosis is difficult, especially in the early stages, because many of the symptoms are similar to Parkinson\u2019s disease. Autonomic testing, assessment of bladder function, and\/or neuroimaging such as an MRI or PET scan are examples of diagnostic examinations. The diagnosis of multiple system atrophy is also dependent on a thorough medical history and neurological exams; the labels Possible, Probable, and Definite are used to describe different diagnostic phases in MSA cases.","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/multiple-system-atrophy-treatment#faq-question-1687147390472","position":4,"url":"https:\/\/www.delveinsight.com\/blog\/multiple-system-atrophy-treatment#faq-question-1687147390472","name":"4. What are the current multiple system atrophy treatment options?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"There are currently no treatments available to slow the progression of multiple system atrophy\u2019s neurodegenerations. There are drugs available to help with multiple system atrophy symptoms, such as Levodopa, Amantadine, Droxidopa, Anticholinergic agents, and various off-label therapy.","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/multiple-system-atrophy-treatment#faq-question-1757481549608","position":5,"url":"https:\/\/www.delveinsight.com\/blog\/multiple-system-atrophy-treatment#faq-question-1757481549608","name":"What is multiple system atrophy prevalence?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"In the assessment done by DelveInsight, the estimated total diagnosed prevalent cases of multiple system atrophy in the 7MM were ~70K in 2024. The highest diagnosed prevalent cases of multiple system atrophy were found to be reported in the US compared to the other 7MM countries.","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/multiple-system-atrophy-treatment#faq-question-1757481556145","position":6,"url":"https:\/\/www.delveinsight.com\/blog\/multiple-system-atrophy-treatment#faq-question-1757481556145","name":"What are the current multiple system atrophy treatment options?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"The drug used to treat Parkinson\u2019s disease, most notably levodopa (SINEMET), is used for multiple system atrophy treatment. Other Parkinson\u2019s disease drugs, in addition to levodopa, may be used to treat multiple system atrophy patients. These included dopamine agonists like ropinirole (REQUIP), pramipexole (MIRAPEXIN), and Midodrine hydrochloride (PROAMATINE), among others.","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/multiple-system-atrophy-treatment#faq-question-1757481566024","position":7,"url":"https:\/\/www.delveinsight.com\/blog\/multiple-system-atrophy-treatment#faq-question-1757481566024","name":"Which are the emerging MSA drugs in the clinical trial landscape?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"H Lundbeck A\/S (Lu AF82422), Theravance Biopharma (Ampreloxetine), AstraZeneca\/Takeda Pharma (TAK-341\/MEDI1341), Ono Pharma (ONO-2808), Teva Pharmaceutical\/MODAG GmbH (Emrusolmin), Ionis Pharmaceuticals, Inc.\/Biogen (ION464), Alterity Therapeutics (ATH434), and others are the leading companies working in the segment with their lead assets in different multiple system atrophy clinical trials.","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/multiple-system-atrophy-treatment#faq-question-1757481580666","position":8,"url":"https:\/\/www.delveinsight.com\/blog\/multiple-system-atrophy-treatment#faq-question-1757481580666","name":"Where is the multiple system atrophy market headed?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"According to DelveInsight\u2019s analysis, the multiple system atrophy market in the 7MM was valued at approximately USD 43 million in 2023. Over the forecast period from 2024 to 2034, multiple system atrophy market is projected to grow at a CAGR of 44.7%.","inLanguage":"en-US"},"inLanguage":"en-US"}]}},"author_meta":{"display_name":"Jatin Vimal","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/jatin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/06\/19093701\/multiple-system-atrophy-treatment-300x200.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Articles<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Articles<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Multiple System Atrophy<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Multiple System Atrophy Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Multiple System Atrophy Patients<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Multiple System Atrophy Treatment<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Multiple System Atrophy Treatment Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Parkinson\u2019s disease<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Samsara BioCapital<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Multiple System Atrophy<\/span>","<span class=\"advgb-post-tax-term\">Multiple System Atrophy Market<\/span>","<span class=\"advgb-post-tax-term\">Multiple System Atrophy Patients<\/span>","<span class=\"advgb-post-tax-term\">Multiple System Atrophy Treatment<\/span>","<span class=\"advgb-post-tax-term\">Multiple System Atrophy Treatment Market<\/span>","<span class=\"advgb-post-tax-term\">Parkinson\u2019s disease<\/span>","<span class=\"advgb-post-tax-term\">Samsara BioCapital<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 8 months ago","modified":"Updated 7 months ago"},"absolute_dates":{"created":"Posted on Aug 22, 2025","modified":"Updated on Sep 10, 2025"},"absolute_dates_time":{"created":"Posted on Aug 22, 2025 5:06 pm","modified":"Updated on Sep 10, 2025 10:49 am"},"featured_img_caption":"multiple-system-atrophy-treatment","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/23646","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/20"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=23646"}],"version-history":[{"count":2,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/23646\/revisions"}],"predecessor-version":[{"id":33325,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/23646\/revisions\/33325"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/23647"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=23646"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=23646"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=23646"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=23646"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=23646"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}